Sofinnova Ventures Adds Biotechnology Executive Dr. David Kabakoff to the Life Science Team

Kabakoff Strengthens Sofinnova Presence in San Diego Market

May 30, 2007, 01:00 ET from Sofinnova Ventures

    SAN FRANCISCO, May 30 /PRNewswire/ -- Sofinnova Ventures, a venture
 capital firm investing in early-stage life science and information
 technology companies, today announced that the firm is expanding with the
 addition of noted entrepreneur and biotechnology professional David
 Kabakoff, Ph.D. in its San Diego, CA office. Following the appointment of
 Bill Ringo to the Sofinnova life science team earlier this month, the firm
 continues to add seasoned professionals. David will hold the role of
 Executive-in-Residence and manage the San Diego office. His chief
 responsibilities will be to participate in identifying and vetting
 prospective companies for funding, both in the San Diego region and
 elsewhere, and to offer his direct experience by coaching portfolio company
 CEOs in leading successful businesses.
     "David has held a long-term relationship with Sofinnova, and we're
 delighted to make it official," said Mike Powell, Ph.D. and General Partner
 of Sofinnova Ventures. "With David's excellent track record and established
 reputation for founding and holding senior positions within pharmaceutical
 companies, we are assured that he will be a strong asset for Sofinnova and
 our portfolio companies. Furthermore, David is the clear choice to lead our
 firm's San Diego office and to help Sofinnova expand in the San Diego
 market through his strong connections in both the local academic and
 business communities."
     New Executive-in-Residence Appointment
     David Kabakoff has 30 years of experience leading technology and
 product development programs in the pharmaceutical, biopharmaceutical and
 drug delivery fields. Before establishing a strategic consulting practice,
 David co-founded Salmedix, Inc., a developer of cancer drug treatments, and
 served as the company's Chairman and Chief Executive Officer. In June 2005,
 David negotiated the acquisition of Salmedix by Cephalon, Inc. for $200
 Million. David also held the positions of Executive Vice President and
 President while at Dura Pharmaceuticals, a specialty respiratory
 pharmaceutical and pulmonary drug delivery company. Earlier, David was also
 employed as a Chief Executive Officer of Spiros Development Corp., Chief
 Executive Officer of Corvas International and held senior executive
 positions with Hybritech.
     He currently serves as Chairman of Trius Therapeutics (a Sofinnova
 Ventures portfolio company), Chairman of Amplimmune, Inc., and as a
 Director of Intermune, Inc., Avalon Pharmaceuticals, Inc. and Alylix, Inc.
 David received his Ph.D. from Yale University and his B.A. from Case
 Western Reserve University.
     San Diego Office
     The San Diego office marks the first satellite office for Sofinnova
 Ventures, a San Francisco, CA-based firm. San Diego has been targeted as a
 prime geographic region for Sofinnova due to the significant number of new
 companies being established in both life science and IT. Sofinnova's
 current San Diego portfolio companies include: Ascenta Therapeutics, Ocera,
 Orexigen, Phenomix, Trius Therapeutics, and Tensys Medical. Sofinnova's
 office will be centrally located in the BIOCOM VC Suites located at 4510
 Executive Drive, Suite 206.
     About Sofinnova Ventures
     Founded in 1974, Sofinnova Ventures is a leading venture capital firm
 specializing in spin offs and emphasizing a diversified investment strategy
 through the financing of early stage companies in the life science and
 information technology sectors. Sofinnova's mission is to create value by
 providing entrepreneurs with the resources, experience and networks
 necessary to turn their ideas into profitable businesses. For more
 information, visit
     Press contact:
     Carol Wentworth
     Director of Marketing
     Sofinnova Ventures
     415-228-3395 (office)

SOURCE Sofinnova Ventures